Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus CEPHALOTHIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus CEPHALOTHIN SODIUM.
AVYCAZ vs CEPHALOTHIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Cephalothin is a first-generation cephalosporin with bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs).
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
Terminal elimination half-life: 0.5-1.0 hour in adults with normal renal function. In anuria, prolonged to 2.5-8 hours. Dose adjustment required for CrCl <50 mL/min.
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion). Minor biliary excretion (1-5%). Fecal elimination negligible.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic